SGLT2 Inhibitors Market

SGLT2 Inhibitors Market Size, Share, Competitive Landscape and Trend Analysis Report by Drug, Indication, and Distribution Channel: Global Opportunity and Industry Forecast (2024-2030)

Report ID:

1075

Industry:

Healthcare

Published on:

Oct 2025

1. SGLT2 Inhibitors Market: Overview

1.1. Study Assumption and Market Definition

1.2. Scope of the Study

1.3. Executive Summary

1.3.1. Market Size and Market Share by Segments, Region and Country

2. SGLT2 Inhibitors Market: Market Variables and Key Insights

2.1. SGLT2 Inhibitors Market Dynamics

2.1.1. Market Trends Analysis

2.1.2. Market Drivers Analysis

2.1.3. Market Challenges Analysis

2.1.4. Market Opportunities Analysis

2.2. SGLT2 Inhibitors Market Business Tools Analysis

2.2.1. PORTER’s Five Forces Analysis

2.2.2. PESTLE Analysis

2.3. Technology Roadmap

2.4. Value Chain Analysis

2.5. Regulatory Landscape by Region

2.5.1. North America

2.5.2. Europe

2.5.3. Asia Pacific

2.5.4. Middle East and Africa

2.5.5. South America

2.6. Analysis of Government Schemes and Initiatives on the Global SGLT2 Inhibitors Market

3. SGLT2 Inhibitors Market: Global Market Size, Trend Analysis and Forecast (2024-2030) in Value (USD Million)

3.1. Global SGLT2 Inhibitors Market Size and Forecast, By Drug (2024-2030)

3.1.1. Jardiance (empagliflozin)

3.1.2. Farxiga (dapagliflozin)

3.1.3. Invokana (canagliflozin)

3.1.4. Inpefa (sotagliflozin)

3.1.5. Qtern (dapagliflozin/saxagliptin)

3.1.6. Other SGLT2 Inhibitors

3.2. Global SGLT2 Inhibitors Market Size and Forecast, By Indication (2024-2030)

3.2.1. Type 2 Diabetes

3.2.2. Cardiovascular

3.2.3. Chronic Kidney Disease (CKD)

3.2.4. Others

3.3. Global SGLT2 Inhibitors Market Size and Forecast, By Distribution Channel (2024-2030)

3.3.1. Hospital Pharmacies

3.3.2. Retail Pharmacies

3.3.3. Online Pharmacies

3.4. Global SGLT2 Inhibitors Market Size and Forecast, By Country (2024-2030)

3.4.1. North America

3.4.2. Europe

3.4.3. Asia Pacific

3.4.4. Middle East & Africa

3.4.5. South America

4. SGLT2 Inhibitors Market: North America Market Size, Trend Analysis and Forecast (2024-2030) in Value (USD Million)

4.1. North America SGLT2 Inhibitors Market Size and Forecast, By Drug (2024-2030)

4.1.1. Jardiance (empagliflozin)

4.1.2. Farxiga (dapagliflozin)

4.1.3. Invokana (canagliflozin)

4.1.4. Inpefa (sotagliflozin)

4.1.5. Qtern (dapagliflozin/saxagliptin)

4.1.6. Other SGLT2 Inhibitors

4.2. North America SGLT2 Inhibitors Market Size and Forecast, By Indication (2024-2030)

4.2.1. Type 2 Diabetes

4.2.2. Cardiovascular

4.2.3. Chronic Kidney Disease (CKD)

4.2.4. Others

4.3. North America SGLT2 Inhibitors Market Size and Forecast, By Distribution Channel (2024-2030)

4.3.1. Hospital Pharmacies

4.3.2. Retail Pharmacies

4.3.3. Online Pharmacies

4.4. North America SGLT2 Inhibitors Market Size and Forecast, by Country (2024-2030)

4.4.1. United States

4.4.2. Mexico

4.4.3. Canada

4.4.1.1. United States SGLT2 Inhibitors Market Size and Forecast, By Drug (2024-2030)

4.4.1.2. United States SGLT2 Inhibitors Market Size and Forecast, By Indication (2024-2030)

4.4.1.3. United States SGLT2 Inhibitors Market Size and Forecast, By Distribution Channel (2024-2030)

4.4.2.1. Mexico SGLT2 Inhibitors Market Size and Forecast, By Drug (2024-2030)

4.4.2.2. Mexico SGLT2 Inhibitors Market Size and Forecast, By Indication (2024-2030)

4.4.2.3. Mexico SGLT2 Inhibitors Market Size and Forecast, By Distribution Channel (2024-2030)

4.4.3.1. Canada SGLT2 Inhibitors Market Size and Forecast, By Drug (2024-2030)

4.4.3.2. Canada SGLT2 Inhibitors Market Size and Forecast, By Indication (2024-2030)

4.4.3.3. Canada SGLT2 Inhibitors Market Size and Forecast, By Distribution Channel (2024-2030)

5. SGLT2 Inhibitors Market: Europe Market Size, Trend Analysis and Forecast (2024-2030) in Value (USD Million)

5.1. Europe SGLT2 Inhibitors Market Size and Forecast, By Drug (2024-2030)

5.1.1. Jardiance (empagliflozin)

5.1.2. Farxiga (dapagliflozin)

5.1.3. Invokana (canagliflozin)

5.1.4. Inpefa (sotagliflozin)

5.1.5. Qtern (dapagliflozin/saxagliptin)

5.1.6. Other SGLT2 Inhibitors

5.2. Europe SGLT2 Inhibitors Market Size and Forecast, By Indication (2024-2030)

5.2.1. Type 2 Diabetes

5.2.2. Cardiovascular

5.2.3. Chronic Kidney Disease (CKD)

5.2.4. Others

5.3. Europe SGLT2 Inhibitors Market Size and Forecast, By Distribution Channel (2024-2030)

5.3.1. Hospital Pharmacies

5.3.2. Retail Pharmacies

5.3.3. Online Pharmacies

5.4. Europe SGLT2 Inhibitors Market Size and Forecast, By Country (2024-2030)

5.4.1. United Kingdom

5.4.2. France

5.4.3. Germany

5.4.4. Italy

5.4.5. Spain

5.4.6. Sweden

5.4.7. Russia

5.4.8. Rest of Europe

5.4.1.1. United Kingdom SGLT2 Inhibitors Market Size and Forecast, By Drug (2024-2030)

5.4.1.2. United Kingdom SGLT2 Inhibitors Market Size and Forecast, By Indication (2024-2030)

5.4.1.3. United Kingdom SGLT2 Inhibitors Market Size and Forecast, By Distribution Channel (2024-2030)

5.4.2.1. France SGLT2 Inhibitors Market Size and Forecast, By Drug (2024-2030)

5.4.2.2. France SGLT2 Inhibitors Market Size and Forecast, By Indication (2024-2030)

5.4.2.3. France SGLT2 Inhibitors Market Size and Forecast, By Distribution Channel (2024-2030)

5.4.3.1. Germany SGLT2 Inhibitors Market Size and Forecast, By Drug (2024-2030)

5.4.3.2. Germany SGLT2 Inhibitors Market Size and Forecast, By Indication (2024-2030)

5.4.3.3. Germany SGLT2 Inhibitors Market Size and Forecast, By Distribution Channel (2024-2030)

5.4.4.1. Italy SGLT2 Inhibitors Market Size and Forecast, By Drug (2024-2030)

5.4.4.2. Italy SGLT2 Inhibitors Market Size and Forecast, By Indication (2024-2030)

5.4.4.3. Italy SGLT2 Inhibitors Market Size and Forecast, By Distribution Channel (2024-2030)

5.4.5.1. Spain SGLT2 Inhibitors Market Size and Forecast, By Drug (2024-2030)

5.4.5.2. Spain SGLT2 Inhibitors Market Size and Forecast, By Indication (2024-2030)

5.4.5.3. Spain SGLT2 Inhibitors Market Size and Forecast, By Distribution Channel (2024-2030)

5.4.6.1. Sweden SGLT2 Inhibitors Market Size and Forecast, By Drug (2024-2030)

5.4.6.2. Sweden SGLT2 Inhibitors Market Size and Forecast, By Indication (2024-2030)

5.4.6.3. Sweden SGLT2 Inhibitors Market Size and Forecast, By Distribution Channel (2024-2030)

5.4.7.1. Russia SGLT2 Inhibitors Market Size and Forecast, By Drug (2024-2030)

5.4.7.2. Russia SGLT2 Inhibitors Market Size and Forecast, By Indication (2024-2030)

5.4.7.3. Russia SGLT2 Inhibitors Market Size and Forecast, By Distribution Channel (2024-2030)

5.4.8.1. Rest of Europe SGLT2 Inhibitors Market Size and Forecast, By Drug (2024-2030)

5.4.8.2. Rest of Europe SGLT2 Inhibitors Market Size and Forecast, By Indication (2024-2030)

5.4.8.3. Rest of Europe SGLT2 Inhibitors Market Size and Forecast, By Distribution Channel (2024-2030)

6. SGLT2 Inhibitors Market: Asia Pacific Market Size, Trend Analysis and Forecast (2024-2030) in Value (USD Million)

6.1. Asia Pacific SGLT2 Inhibitors Market Size and Forecast, By Drug (2024-2030)

6.1.1. Jardiance (empagliflozin)

6.1.2. Farxiga (dapagliflozin)

6.1.3. Invokana (canagliflozin)

6.1.4. Inpefa (sotagliflozin)

6.1.5. Qtern (dapagliflozin/saxagliptin)

6.1.6. Other SGLT2 Inhibitors

6.2. Asia Pacific SGLT2 Inhibitors Market Size and Forecast, By Indication (2024-2030)

6.2.1. Type 2 Diabetes

6.2.2. Cardiovascular

6.2.3. Chronic Kidney Disease (CKD)

6.2.4. Others

6.3. Asia Pacific SGLT2 Inhibitors Market Size and Forecast, By Distribution Channel (2024-2030)

6.3.1. Hospital Pharmacies

6.3.2. Retail Pharmacies

6.3.3. Online Pharmacies

6.4. Asia Pacific SGLT2 Inhibitors Market Size and Forecast, By Country (2024-2030)

6.4.1. China

6.4.2. South Korea

6.4.3. Japan

6.4.4. India

6.4.5. Australia

6.4.6. ASEAN

6.4.7. Rest of Asia Pacific

6.5.1.1. China SGLT2 Inhibitors Market Size and Forecast, By Drug (2024-2030)

6.5.1.2. China SGLT2 Inhibitors Market Size and Forecast, By Indication (2024-2030)

6.5.1.3. China SGLT2 Inhibitors Market Size and Forecast, By Distribution Channel (2024-2030)

6.5.2.1. South Korea SGLT2 Inhibitors Market Size and Forecast, By Drug (2024-2030)

6.5.2.2. South Korea SGLT2 Inhibitors Market Size and Forecast, By Indication (2024-2030)

6.5.2.3. South Korea SGLT2 Inhibitors Market Size and Forecast, By Distribution Channel (2024-2030)

6.5.3.1. Japan SGLT2 Inhibitors Market Size and Forecast, By Drug (2024-2030)

6.5.3.2. Japan SGLT2 Inhibitors Market Size and Forecast, By Indication (2024-2030)

6.5.3.3. Japan SGLT2 Inhibitors Market Size and Forecast, By Distribution Channel (2024-2030)

6.5.4.1. India SGLT2 Inhibitors Market Size and Forecast, By Drug (2024-2030)

6.5.4.2. India SGLT2 Inhibitors Market Size and Forecast, By Indication (2024-2030)

6.5.4.3. India SGLT2 Inhibitors Market Size and Forecast, By Distribution Channel (2024-2030)

6.5.5.1. Australia SGLT2 Inhibitors Market Size and Forecast, By Drug (2024-2030)

6.5.5.2. Australia SGLT2 Inhibitors Market Size and Forecast, By Indication (2024-2030)

6.5.5.3. Australia SGLT2 Inhibitors Market Size and Forecast, By Distribution Channel (2024-2030)

6.5.6.1. ASEAN SGLT2 Inhibitors Market Size and Forecast, By Drug (2024-2030)

6.5.6.2. ASEAN SGLT2 Inhibitors Market Size and Forecast, By Indication (2024-2030)

6.5.6.3. ASEAN SGLT2 Inhibitors Market Size and Forecast, By Distribution Channel (2024-2030)

6.4.7.1. Rest of Asia Pacific SGLT2 Inhibitors Market Size and Forecast, By Drug (2024-2030)

6.4.7.2. Rest of Asia Pacific SGLT2 Inhibitors Market Size and Forecast, By Indication (2024-2030)

6.4.7.3. Rest of Asia Pacific SGLT2 Inhibitors Market Size and Forecast, By Distribution Channel (2024-2030)

7. SGLT2 Inhibitors Market: Middle East & Africa Market Size, Trend Analysis and Forecast (2024-2030) in Value (USD Million)

7.1. Middle East & Africa SGLT2 Inhibitors Market Size and Forecast, By Drug (2024-2030)

7.1.1. Jardiance (empagliflozin)

7.1.2. Farxiga (dapagliflozin)

7.1.3. Invokana (canagliflozin)

7.1.4. Inpefa (sotagliflozin)

7.1.5. Qtern (dapagliflozin/saxagliptin)

7.1.6. Other SGLT2 Inhibitors

7.2. Middle East & Africa SGLT2 Inhibitors Market Size and Forecast, By Indication (2024-2030)

7.2.1. Type 2 Diabetes

7.2.2. Cardiovascular

7.2.3. Chronic Kidney Disease (CKD)

7.2.4. Others

7.3. Middle East & Africa SGLT2 Inhibitors Market Size and Forecast, By Distribution Channel (2024-2030)

7.3.1. Hospital Pharmacies

7.3.2. Retail Pharmacies

7.3.3. Online Pharmacies

7.4. Middle East & Africa SGLT2 Inhibitors Market Size and Forecast, by Country (2024-2030)

7.4.1. South Africa

7.4.2. GCC

7.4.3. Turkey

7.4.4. Rest of ME&A

7.5.1.1. South Africa SGLT2 Inhibitors Market Size and Forecast, By Drug (2024-2030)

7.5.1.2. South Africa SGLT2 Inhibitors Market Size and Forecast, By Indication (2024-2030)

7.5.1.3. South Africa SGLT2 Inhibitors Market Size and Forecast, By Distribution Channel (2024-2030)

7.5.2.1. GCC SGLT2 Inhibitors Market Size and Forecast, By Drug (2024-2030)

7.5.2.2. GCC SGLT2 Inhibitors Market Size and Forecast, By Indication (2024-2030)

7.5.2.3. GCC SGLT2 Inhibitors Market Size and Forecast, By Distribution Channel (2024-2030)

7.5.3.1. Turkey SGLT2 Inhibitors Market Size and Forecast, By Drug (2024-2030)

7.5.3.2. Turkey SGLT2 Inhibitors Market Size and Forecast, By Indication (2024-2030)

7.5.3.3. Turkey SGLT2 Inhibitors Market Size and Forecast, By Distribution Channel (2024-2030)

7.4.4.1. Rest of ME&A SGLT2 Inhibitors Market Size and Forecast, By Drug (2024-2030)

7.4.4.2. Rest of ME&A SGLT2 Inhibitors Market Size and Forecast, By Indication (2024-2030)

7.4.4.3. Rest of ME&A SGLT2 Inhibitors Market Size and Forecast, By Distribution Channel (2024-2030)

8. SGLT2 Inhibitors Market: South America Market Size, Trend Analysis and Forecast (2024-2030) in Value (USD Million)

8.1. South America SGLT2 Inhibitors Market Size and Forecast, By Drug (2024-2030)

8.1.1. Jardiance (empagliflozin)

8.1.2. Farxiga (dapagliflozin)

8.1.3. Invokana (canagliflozin)

8.1.4. Inpefa (sotagliflozin)

8.1.5. Qtern (dapagliflozin/saxagliptin)

8.1.6. Other SGLT2 Inhibitors

8.2. South America SGLT2 Inhibitors Market Size and Forecast, By Indication (2024-2030)

8.2.1. Type 2 Diabetes

8.2.2. Cardiovascular

8.2.3. Chronic Kidney Disease (CKD)

8.2.4. Others

8.3. South America SGLT2 Inhibitors Market Size and Forecast, By Distribution Channel (2024-2030)

8.3.1. Hospital Pharmacies

8.3.2. Retail Pharmacies

8.3.3. Online Pharmacies

8.4. South America SGLT2 Inhibitors Market Size and Forecast, by Country (2024-2030)

8.4.1. Brazil

8.4.2. Argentina

8.4.3. Rest of South America

8.5.1.1. Brazil SGLT2 Inhibitors Market Size and Forecast, By Drug (2024-2030)

8.5.1.2. Brazil SGLT2 Inhibitors Market Size and Forecast, By Indication (2024-2030)

8.5.1.3. Brazil SGLT2 Inhibitors Market Size and Forecast, By Distribution Channel (2024-2030)

8.5.2.1. Argentina SGLT2 Inhibitors Market Size and Forecast, By Drug (2024-2030)

8.5.2.2. Argentina SGLT2 Inhibitors Market Size and Forecast, By Indication (2024-2030)

8.5.2.3. Argentina SGLT2 Inhibitors Market Size and Forecast, By Distribution Channel (2024-2030)

8.4.3.1. Rest of South America SGLT2 Inhibitors Market Size and Forecast, By Drug (2024-2030)

8.4.3.2. Rest of South America SGLT2 Inhibitors Market Size and Forecast, By Indication (2024-2030)

8.4.3.3. Rest of South America SGLT2 Inhibitors Market Size and Forecast, By Distribution Channel (2024-2030)

9. SGLT2 Inhibitors Market: Competitive Landscape

9.1. JBI Competition Matrix

9.2. Competitive Landscape

9.3. Key Players Benchmarking

1. Company Name

2. Product Segment

3. End-User Segment

4. Revenue Details

5. Market Share

6. Company Locations

9.4. Market Categorisation

1. Market Leaders

2. Market Followers

3. Market Emerging Players

4. Mergers and Acquisitions Details

9.5. Company Profiles of Leading Market Players (Company Overview, Product Portfolio, Financial Overview, SWOT Analysis, Strategies, Recent Developments, (Based on Availability))

1. Company Name

2. Product Segment

3. End-User Segment

4. Revenue Details

5. Market Share

6. Company Locations

9.5.1. AstraZeneca

9.5.2. Boehringer Ingelheim

9.5.3. Eli Lilly

9.5.4. Johnson & Johnson

9.5.5. Merck & Co.

9.5.6. Pfizer

9.5.7. Sanofi

9.5.8. Novo Nordisk

9.5.9. Glenmark Pharmaceuticals

9.5.10. Sun Pharmaceutical Industries

9.5.11. Lexicon Pharmaceuticals

9.5.12. Mitsubishi Tanabe Pharma

9.5.13. Taisho Pharmaceutical

9.5.14. Sumitomo Dainippon Pharma

9.5.15. Bristol-Myers Squibb

10. SGLT2 Inhibitors Market: Strategic Recommendations/ Market Opportunities

11. SGLT2 Inhibitors Market: Key Takeaways

12. SGLT2 Inhibitors Market: Research Methodology

Note:

The table of contents is as per our syndicate report aimed at a broader audience, can be modified as per requirements.
TOC can be amended before delivery as per research updates by the analysts.

Global SGLT2 Inhibitors Market had a value of USD 17.6 billion in 2024 and expected it to hit USD 27.12 billion by 2030, with a CAGR of 7.47 % through the forecast period.

SGLT2 Inhibitors Market Overview

SGLT2 Inhibitors Market in 2024 was really turning out to be very popular. The main reason for this positive trend was the global rise in chronic disease cases. More than 500 million people globally suffer from diabetes, and it is predicted that the number will rise to 640 million by 2030, thus creating a very large patient base. In the United States, there are more than 37 million diabetics, which was the reason why the country ranks first in this market. On the other hand, the Europe contains almost 60 million diabetic patients, and with the number of heart failure cases exceeding 15 million, the region was becoming a very large market for these drugs. At present, clinical guidelines have fully promoted SGLT2 inhibitors as a main source of both cardiovascular and renal protection.

By 2024, The SGLT2 inhibitors market was also shaped by strong pharmaceutical innovation and competitive activity. There were more than ten different branded drugs available globally, the top ones was Jardiance, Farxiga, and Invokana, which lead to annual revenues of over 1 billion dollars each. Just in 2024, Jardiance managed to make sales worth over 6 billion US dollars, which expresses volumes about the high consumption of these drugs. Besides, over 150 clinical trials were currently underway looking for new indications such as obesity and liver disease that could significantly increase the patient base. It was estimated that patent expirations after 2026 will be the point of origin for generic versions that will most likely raise affordability and accessibility for SGLT2 Inhibitors Market. These and other factors, such as the strong R&D pipelines and the presence of strategic alliances, are truly indicative of the SGLT2 Inhibitors Market ability to hold a strong future.

The report by Jadhavar Business Intelligence Pvt. Ltd. delivers a comprehensive analysis of the SGLT2 Inhibitors Market, covering global, regional, and country-level insights from 2024 to 2030. It includes an overview of market definitions, assumptions, and scope, along with detailed market size, share, and segment analysis by Drug, Indication and Distribution Channel. The report provides in-depth market dynamics, trends, drivers, challenges, and opportunities, supported by analytical tools such as PORTER’s Five Forces, PESTLE, technology roadmaps, value chain mapping, and regulatory landscape assessments. Regional deep-dives cover North America, Europe, Asia Pacific, Middle East & Africa, and South America, with country-level forecasts. The competitive landscape section benchmarks leading players, profiles key companies, and analyses strategic developments. The report concludes with strategic recommendations, market opportunities, and key takeaways to guide business decision-making.

SGLT2 Inhibitors Market Dynamic’s

In 2024 SGLT2 inhibitors market was mainly driven by the coverage of the healthcare system and insurance, which facilitates access to new treatments. Globally, more than 70% of patients with type 2 diabetes receive some form of reimbursement support, leading to the higher utilization of the therapy. Besides, the SGLT2 Inhibitors Market advancement in drug delivery technology, e.g., the once-daily oral formulations, had resulted in the patient's compliance, with the adherence rate increasing by 15-20% compared to the older therapies. The increase in awareness campaigns led by pharma and medical associations, who are educating over 1 billion people globally about diabetes management, is another factor providing the SGLT2 Inhibitors Market demand further push.

SGLT2 inhibitors market faced a number of challenges and restrictions that may have an adverse impact on its overall growth. The price of therapy was the biggest issue for the SGLT2 Inhibitors Market, which was usually from USD 300 to 500 per month in major markets, and this mainly affects the situation in less developed countries. Concerns about safety, for instance, urinary tract infections that occur in 8-12% of patients and very few cases of ketoacidosis (~0.5% incidence) was also raising the caution of these medications' usage. Numerous countries such as India and Brazil where the regulations and approval are slow may also be the reasons for the late market entry. Besides, it was still worth noting that the old diabetes drugs were a barrier for the diabetes market to go deeper.

SGLT2 inhibitors market in 2024 present’s significant opportunities for growth and innovation. The broadly accepted indications enabled this market to move beyond diabetes to heart failure, chronic kidney disease, and obesity, which were new patient segments that might contain more than 100 million targets globally. The developing markets in Asia-Pacific and Latin America where the number of diabetes cases was increasing by 5–7% each year offer a large volume of the market that was not yet served. Advances in fixed-dose combinations and once-daily oral formulations have led to patient compliance, thus there was the potential for further penetration. Furthermore, an ongoing clinical trial for new therapeutic benefits, together with the deployment of the digital health sector for patient monitoring, gives pharma companies new ways to be different and capture the SGLT2 Inhibitors Market.

SGLT2 Inhibitors Market Segment Analysis

The SGLT2 Inhibitors Market segmented into By Drug, By Indication, and By Distribution Channel.

By Drug

Based on Drug, the market is segmented into Jardiance (empagliflozin), Farxiga (dapagliflozin), Invokana (canagliflozin), Inpefa (sotagliflozin), Qtern (dapagliflozin/saxagliptin) and Other SGLT2 Inhibitors. In 2024, the Jardiance (empagliflozin) segment dominated the SGLT2 Inhibitors Market, accounted for 55% of the total market share. This dominance was driven by strong clinical evidence showing significant cardiovascular and renal benefits for type 2 diabetes patients. Expanded approval for heart failure and kidney disease further boosted its adoption. Jardiance’s broad clinical profile and market positioning solidified its top position in 2024.

By Indication

Based on the Indication, the market is categorized into Type 2 Diabetes, Cardiovascular, Chronic Kidney Disease (CKD) and others. In 2024, the Type 2 Diabetes segment dominated the SGLT2 inhibitors market, accounting for approximately 60% of the global share. This dominance is owing to the large patient base, with over 500 million people globally living with diabetes, and the drugs’ proven effectiveness in controlling blood sugar. Early approvals and strong clinical evidence for cardiovascular and kidney benefits also reinforced their primary use in diabetes management, making Type 2 Diabetes the leading indication sub segment.

SGLT2 Inhibitors Market Region Analysis

In 2024, North America dominated the SGLT2 inhibitors market, held around 45% of the global share. The region's supremacy was basically owing to the high occurrence of type 2 diabetes, the existence of a well-established healthcare infrastructure, the wide availability of insurance, and the early implementation of new treatments. To be more specific, the U.S. was the main recipient of complete clinical guideline support which directs the use of SGLT2 inhibitors for diabetes, heart failure, and kidney disease.

Europe was next with almost a remarkable share of 30%, propelled by good reimburses and growing recognition of the cardiovascular and renal benefits. The Asia-Pacific and Latin American regions were slow yet steady growers in these markets, which together accounted for about 25% of the global SGLT2 Inhibitors Market, the drivers being the prevalence of diabetes, healthcare spending, and the facilitation of access to innovative therapies.

SGLT2 Inhibitors Market Competitive Analysis

In 2024, AstraZeneca, in partnership with Boehringer Ingelheim, appeared as the dominant player in the SGLT2 inhibitors market, capturing around 35% of the global SGLT2 Inhibitors Market share, largely driven by the success of Farxiga and Jardiance. The introduction of strong clinical evidence, wide-ranging approvals for indications, and aggressive marketing were the main elements that facilitated the dominance of the company. Besides, there were also several other major pharmaceutical companies in the market such as Eli Lilly, Johnson & Johnson, Merck, and Pfizer whose shares are relatively smaller and range between 5–10% each. Products like Invokana and Qtern support them and are very competitive in the SGLT2 Inhibitors Market. The new entrants in the field such as Lexicon, Glenmark, and Sun Pharma are targeting the market segments, partnerships, and geographical expansions to increase their position and challenge the market leaders.

SGLT2 Inhibitors Market Summary:

The SGLT2 inhibitors market in 2024 was witnessing strong growth, driven by rising awareness of diabetes management and associated cardiovascular and kidney benefits. Jardiance led the drug segment due to its broad clinical efficacy, while Type 2 Diabetes remained the dominant indication because of the large patient base and proven therapeutic outcomes. North America held the largest share, supported by advanced healthcare infrastructure, insurance coverage, and early adoption of innovative therapies. Europe showed steady growth with favorable reimbursement policies, while Asia-Pacific and Latin America present emerging opportunities. Ongoing clinical trials, digital health integration, and advancements in drug formulations are further enhancing market potential and patient compliance.

SGLT2 Inhibitors Market Scope:

SGLT2 Inhibitors Market Key Players –

AstraZeneca
Boehringer Ingelheim
Eli Lilly
Johnson & Johnson
Merck & Co.
Pfizer
Sanofi
Novo Nordisk
Glenmark Pharmaceuticals
Sun Pharmaceutical Industries
Lexicon Pharmaceuticals
Mitsubishi Tanabe Pharma
Taisho Pharmaceutical
Sumitomo Dainippon Pharma
Bristol-Myers Squibb

SGLT2 Inhibitors Market Frequently Ask Questions –

1) Who are the major key players of the SGLT2 Inhibitors Market?

Ans - Major players include AstraZeneca, Boehringer Ingelheim, Eli Lilly, Johnson & Johnson, and Merck & Co.

2) Which region accounted for the highest market share in 2024 for the SGLT2 Inhibitors Market?

Ans - North America accounted for the highest market share in 2024 for the SGLT2 Inhibitors Market.

3) What was the SGLT2 Inhibitors Market size in 2024?

Ans - The SGLT2 Inhibitors Market was valued at USD 17.6 billion in 2024.

4) Which segment is expected to lead the SGLT2 Inhibitors Market during the forecast period?

Ans - The Drug segment is expected to remain the leading category during the forecast period

5) What will the market size of SGLT2 Inhibitors Market in 2030?

Ans – The market size SGLT2 Inhibitors Market in 2030 will be USD 27.12 billion.

Report Payment

Single User:

$4199

Spreadsheet:

$2900

Corporate User:

$5500

Buy Now

Download Report Sample

Request for Customization

Speak with Analyst